

**Prism Medico And Pharmacy Limited**

Reg. Office : D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email : investorgrievancewmcl@gmail.com

www.prismmedico.com

Date: 01/02/2022

To, Department of Corporate Services, BSE LIMITED P. J. Towers, Dalal Street, Mumbai – 400 001	To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098, India. ISIN : INE730E01016
Scrip Code: 512217	

Dear Sir / Madam,

Subject: Outcome of the Board Meeting held on 01st February 2022, Tuesday, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.


With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Tuesday, 01st February 2022 at 04:00 P.M. concluded at 04:30 P.M. Following transactions were approved:

1. Un-Audited Financial Results for the quarter ending on 31st December 2021.
2. Limited Review Report from the auditor for the quarter ending on 31st December 2021.
3. Authorisation to file application to Central Government for shifting of registered office from the State of Punjab to the State of Himachal Pradesh.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,

Yours Truly,

For **PRISM MEDICO & PHARMACY LIMITED**

Sameer Gupta
Company Secretary

A-59256

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLCO47444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2021 (IN LAKHS)

PARTICULARS	Quarter Ended (Unaudited)			Period Ended (UnAudited)	Period Ended (Unaudited)	Year Ended (Audited)
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
1 INCOME FROM OPERATIONS						
A Net Sales/ Income From Operations	0.00	0.00	606.72	0.00	1244.49	1676.35
B Other Operating Income	0.00	0.00	0.00	0.00	0.00	
TOTAL INCOME FROM OPERATIONS (NET)	0.00	0.00	606.72	0.00	1244.49	1676.35
2 EXPENSES:						
Cost of Material Consumed	0.00	0.00	570.20	0.00	1168.18	2146.71
Change In Inventories	0.00	0.00	-0.32	0.00	-0.32	-479.90
Employee Benefit Expenses	5.01	8.44	0.42	13.45	0.98	16.76
Depreciation	0.23	0.23	0.31	0.69	0.92	1.23
Other expenses	1.45	1.21	0.85	7.88	6.82	9.04
TOTAL EXPENSES	6.69	9.88	571.46	22.02	1176.58	1693.84
PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)	-6.69	-9.88	35.27	-22.02	67.91	-17.49
3 Other Income	0.00	0.00	0.00	0.00	0.00	0.00
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)	-6.69	-9.88	35.27	-22.02	67.91	-17.49
5 Finance Cost	0.00	0.00	0.00	0.00		0.02
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)	-6.69	-9.88	35.27	-22.02	67.91	-17.51
7 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)	-6.69	-9.88	35.27	-22.02	67.91	-17.51
9 TAX EXPENSE:						
(1) Current Tax	0.00	0.00	9.17		17.66	0.00
(2) Deferred Tax	0.0346	0.0346	0.01	0.07	0.02	4.51
(3) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)	-6.72	-9.91	26.09	-22.09	50.23	-13.00
12 Extraordinary Items (Net of Tax * Expense ____ Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00

13	NET PROFIT/(LOSS) FOR THE PERIOD (11 + 12)	-6.72	-9.91	26.09	-22.09	50.23	-13.00
14	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13 + 14 + 15) *	-6.72	-9.91	26.09	-22.09	50.23	-13.00
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	606.34	606.34	606.34	606.34	606.34	606.34
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	664.13	670.85	748.30	664.13	748.30	686.25
19	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):						
	(1)BASIC	-0.01	-0.02	0.04	-0.04	0.08	-0.02
	(2)DILUTED	-0.01	-0.02	0.04	-0.04	0.08	-0.02
	Earnings Per Share (after extraordinary items) (of Rs ___/- each)						
19	(not annualised):						
	(1)BASIC	-0.01	-0.02	0.04	-0.04	0.08	-0.02
	(2)DILUTED	-0.01	-0.02	0.04	-0.04	0.08	-0.02

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 01.02.2022.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.

Place : Mohali

Date: 01/02/2022

FOR & ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LTD.

Ramandeep Singh
Whole Time Director
DIN: 07896086

PRISM MEDICO AND PHARMACY LTD.
CIN : L51109PB2002PLC047444

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON
31ST DECEMBER , 2021

PARTICULARS	31.12.2021	31.03.2021
I. ASSETS		
(1) Non - Current Assets		
(a) Property, Plant and Equipment	484,787	553,409
b) Financial Assets		
(1) Non-Current Investments	19,380,000	19,380,000
b) Deffered Tax Asset	577,757	588,128
(2) Current Assets		
(a) Inventories	48,466,240	48,466,240
b) Financial Assets		
(1) Cash & Cash Equivalent	385,244	841,329
(2) Short Term Loans and advances	6,451,523	10,115,337
(3) Trade Receivables	54,184,248	135,139,412
(c) Other Current Asset	336,741	336,741
TOTAL Rs.	130,266,541	215,420,596.29

II EQUITY AND LIABILITIES

(1) Equity		
(a) Equity Share Capital	60,634,280	60,634,280
(b) Other Equity	66,412,261	68,625,164
(2) Current Liabilities		
a) Financial Liabilities		
(1) Trade Payables	1,193,000	84,438,878
(b) Other Current Liabilities	2,027,000	1,722,275
TOTAL Rs.	130,266,541	215,420,595.56

FOR & ON BEHALF OF THE BOARD

Ramandeep Singh

Whole Time Director

DIN: 07896086



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 31st December 2021 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants



UDIN : 22547759AAAAAC7458